EIB and Commission pledge additional 4.9 billion euros in coronavirus fight

29 June 2020
european_commission_large

The ‘Global Goal: Unite for our Future’ pledging summit organized on Saturday by the European Commission and Global Citizen mobilized 6.15 billion euros ($6.90 billion) in additional funding to help develop and ensure equitable access to coronavirus vaccines, tests and treatments.

The money raised will also support economic recovery in the world’s most fragile regions and communities. The 4.9 billion euros comes on top of the 2 billion euros already pledged by the European Investment Bank (EIB) on 4 May.

This amount includes a 4.9 billion-euro pledge by the European Investment Bank, in partnership with the European Commission, and 485 million euros committed by European Union member states. This brings total pledges under the Coronavirus Global Response pledging marathon, launched by European Commission President Ursula von der Leyen on May 4, to 15.9 billion euros.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical